<![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]>

Advertisement News|Articles|May 9, 2026 The OncFive: Top Oncology Articles for the Week of 5/3 Author(s)OncLive Staff Fact checked by: Kristi Rosa Listen0:00 / 0:00 Key Takeaways Zenocutuzumab gained FDA approval for previously treated NRG1 fusion–positive advanced CCA, supported by 36.8% ORR in eNRGy; key risks include IRRs, ILD/pneumonitis, and LV dysfunction. Guardant360 CDx was approved to detect ESR1 mutations for vepdegestrant eligibility, leveraging VERITAC-2 PFS benefit versus fulvestrant (5.0 vs 2.1 months; HR 0.57) with low discontinuation. FDA accepted a taletrectinib sNDA in ROS1+ NSCLC (action date Jan 4, 2027), showing high ORR and durable systemic/CNS control; confirmatory TRUST-III and adjuvant TRUST-IV are ongoing. VIKTORIA-1 topline results showed gedatolisib plus fulvestrant ± palbociclib improved PFS versus alpelisib plus fulvestrant in PIK3CA-mutant HR+/HER2− disease after CDK4/6 inhibitors, with manageable toxicity. Daraxonrasib produced ORR 35% in second-line RAS G12–mutant PDAC and broad second-line activity with frequent rash/mucositis/diarrhea; NDA and phase 3 registrational programs are planned.SHOW MORE The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more. Advertisement Welcome to OncLive®’s OncFive!Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.Here’s what you may have missed this week:FDA Approves Zenocutuzumab for NRG1 Fusion+ CholangiocarcinomaThe FDA has cleared zenocutuzumab-zbco (Bizengri) for the treatment of adult patients with NRG1 fusion–positive advanced, unresectable, or metastatic cholangiocarcinoma (CCA) who have experienced disease progression on or following previous systemic therapy. The decision was supported by data from the single-arm phase 1/2 eNRGy trial (NCT02912949). In 19 evaluable patients with NRG1 fusion–positive CCA, zenocutuzumab elicited an objective response rate (ORR) of 36.8% (95% CI, 16.3%-61.6%) by blinded independent central review (BICR), with a duration of response (DOR) ranging from 2.8 to 12.9 months. The approval was facilitated through the FDA's national priority voucher pilot program. Key safety considerations include infusion-related reactions (IRRs), interstitial lung disease/pneumonitis, and left ventricular dysfunction, with the most common adverse effects (AEs) including diarrhea, musculoskeletal pain, fatigue, nausea, and IRRs. Zenocutuzumab has also been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for biliary tract cancers as a Category 2A–recommended subsequent-line therapy and Category 2B–recommended first-line therapy for NRG1 fusion–positive CCA.FDA Approves Companion Diagnostic for Vepdegestrant in ESR1+, ER+/HER2-Negative Advanced Breast CancerThe FDA has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for vepdegestrant (Veppanu) in patients with estrogen receptor (ER)–positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations, allowing identification of eligible patients via a noninvasive blood-based test. The decision follows the FDA approval of vepdegestrant, which happened on May 1, 2026, and was supported by findings from the phase 3 VERITAC-2 trial (NCT05654623), in which patients with ESR1-mutated disease who were given vepdegestrant (n = 136) experienced a median progression-free survival (PFS) of 5.0 months (95% CI, 3.7-7.4) vs 2.1 months (95% CI, 1.9-3.5) with fulvestrant (Faslodex; n = 134; HR, 0.57; 95% CI, 0.42-0.77; P = .0001), with confirmed ORRs of 19% (95% CI, 12%-27%) vs 4% (95% CI, 1.6%-10%), respectively. Serious AEs occurred in 9% of vepdegestrant-treated patients (n = 312), and included fracture (1.3%), hepatic injury (0.6%), and prolonged QTc (0.3%). AEs led to permanent discontinuation in 2.9% of patients, dose interruptions in 14%, and dose reductions in 1.9%; AEs proved fatal for 1.0% of patients.FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLCThe FDA has accepted a supplemental new drug application (sNDA) seeking approval of taletrectinib (Ibtrozi) in TKI-naive and TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC), with a target action date of January 4, 2027, incorporating an additional 10 months of data from the pivotal phase 2 TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials. At the data cutoff date of August 2025, TKI-naive patients in TRUST-I (n = 103) had a median DOR of 49.7 months (95% CI, 41.3-not reached [NR]) and a median PFS of 49.6 months (95% CI, 34.5-NR). A pooled analysis presented at the 2026 AACR Annual Meeting showed a confirmed ORR of 89.8% (95% CI, 84.0%-94.1%) and an intracranial ORR (IC-ORR) of 76.5% (95% CI, 50.1%-93.2%) in TKI-naive evaluable patients (n = 157), with a median PFS of 46.1 months (95% CI, 31.8-NR) and median overall survival (OS) that was not reached (95% CI, 47.8-NR). The toxicity profile was consistent with previous reports, with no new documented AEs. Two confirmatory phase 3 trials are ongoing: TRUST-III (NCT06564324) comparing taletrectinib with crizotinib (Xalkori) in ROS1 TKI–naive patients, and TRUST-IV (NCT07154706) examining taletrectinib as adjuvant therapy in patients with resected early-stage ROS1-positive NSCLC.Gedatolisib-Based Combinations Beat Alpelisib-Based SOC in PIK3CA-Mutant HR+ Breast CancerTopline data from the phase 3 VIKTORIA-1 trial (NCT05501886) showed that gedatolisib (PF-05212384) in combination with fulvestrant (Faslodex) and palbociclib (Ibrance) significantly improved PFS vs alpelisib (Piqray) plus fulvestrant in patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer who had progressed on or following previous CDK4/6 inhibitor therapy combined with an aromatase inhibitor. Gedatolisib plus fulvestrant also showed a statistically significant and clinically meaningful PFS improvement vs alpelisib plus fulvestrant, although this comparison was not part of the primary hierarchical testing sequence. Both gedatolisib-based regimens were generally well tolerated with manageable toxicity profiles and no new safety signals identified. Celcuity plans to submit an sNDA to the FDA based on these data, with full results to be shared at the 2026 ASCO Annual Meeting. Separately, an NDA for gedatolisib in PIK3CA wild-type hormone receptor–positive, HER2-negative advanced breast cancer is already under FDA priority review with a Prescription Drug User Fee Act goal date of July 17, 2026, based on previously reported wild-type cohort data from VIKTORIA-1.Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerData from the phase 1/2 RMC-6236-001 trial (NCT05379985), published in the New England Journal of Medicine, showed that daraxonrasib (RMC-6236) had antitumor activity and a manageable toxicity profile across RAS mutations in 168 patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma (PDAC). In patients with RAS G12-mutated PDAC receiving 300 mg as second-line therapy (n = 26), the ORR was 35% (95% CI, 17%-56%), the median DOR was 8.2 months (95% CI, 3.8-not evaluable [NE]), the median PFS was 8.5 months (95% CI, 6.7-10.5), and the median OS was 13.1 months (95% CI, 10.9-NE); among all RAS-mutated patients in the second-line setting (n = 38), the ORR was 29% (95% CI, 15%-46%), the disease control rate was 95% (95% CI, 82%-99%), the median PFS was 8.1 months (95% CI, 5.9-10.1), and the median OS was 15.6 months (95% CI, 10.9-NE). Treatment-related AEs were reported in 96% of patients, with the most common being rash (90%; grade 3 or higher, 7%), stomatitis or mucositis (54%; 4%), and diarrhea (52%; 4%) at the 300-mg dose; no treatment-related deaths were reported. Full RASolute 302 data are planned for presentation at the 2026 ASCO Annual Meeting. Revolution Medicines has announced plans to submit an NDA under the FDA Commissioner's National Priority Voucher pilot program and is examining daraxonrasib in three additional phase 3 registrational trials, including RASolute 303 (NCT07491445) in the first-line PDAC setting.Honorable MentionsThe ESMO Breast Cancer Congress is underway. OncLive asked leading breast oncologists to share the presentations and conversations at the top of their lists. Sign up to access exclusive insights from Sarah Sammons, MD, Paolo Tarantino, MD, PhD, and Sara M. Tolaney, MD, MPH.In an exclusive preview ahead of the 2026 ASCO Annual Meeting (ASCO 2026), Eric K. Singhi, MD, Isabel Preeshagul, DO, MBS, and Jonathan W. Lee, MD, MSc, spotlighted the top presentations anticipated in the field of lung cancer.In another exclusive preview, VK Gadi, MD, PhD, Erika Hamilton, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, and Alexis LeVee, MD, shed light on the triple-negative breast cancer presentations that are among the most anticipated datasets at ASCO 2026.OncLive also spoke with Yara Abdou, MD, MSCR, Jane L. Meisel, MD, FASCO, and the aforementioned breast cancer experts about the top expected updates in hormone receptor–positive and HER2-positive breast cancer at ASCO 2026. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementPost–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerByAshling Wahner May 8th 2026Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDByMike J. Pishvaian, MD, PhDMay 8th 2026Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerByAshling Wahner May 8th 2026FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma ByAshling Wahner May 8th 2026UT MD Anderson Shares Latest Research BreakthroughsByMD Anderson Cancer CenterMay 8th 2026 Latest CMEMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma 2First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC3Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 20264OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 20265Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer